When selecting a safety partner, sponsors need to evaluate whether the provider can support the complete pharmacovigilance process rather than only handle individual reporting tasks. A reliable safety system must continue beyond clinical trial data collection and cover the full pathway from adverse event management to post-market surveillance.
The scope of pharmacovigilance services should include case processing, signal detection, PSUR/PBRER preparation, and regulatory reporting. These capabilities work together to maintain complete safety oversight, support regulatory expectations, and ensure that safety information remains accurate throughout the product lifecycle.
Adverse Event Processing: Evaluating the Foundation of PV Services
Adverse event processing is one of the first capabilities sponsors should review when assessing a pharmacovigilance provider. During clinical trials and after product launch, safety teams must manage large volumes of individual case safety reports from different sources.
A qualified provider should have established procedures for case intake, medical review, data entry, coding, seriousness assessment, and quality control. These processes determine whether safety information is captured accurately and consistently.
Sponsors should also evaluate how the provider manages case workflows, including timelines, documentation standards, and follow-up procedures for incomplete information. Efficient case processing reduces the risk of missing important safety details and provides a reliable data foundation for further evaluation.
Signal Detection: Assessing Safety Monitoring Capability
Beyond processing individual cases, effective pharmacovigilance requires the ability to identify potential safety patterns. Signal detection allows safety teams to evaluate whether repeated events or unusual trends may indicate emerging risks.
When reviewing pharmacovigilance services, sponsors should examine whether the provider has experience with safety data review, trend analysis, and risk assessment processes. A capable partner should be able to combine information from clinical trials, spontaneous reports, scientific literature, and other safety sources.This also requires consistent review processes and experienced safety professionals who can distinguish meaningful signals from expected variations in safety data.
Strong signal detection capabilities help organizations identify possible safety concerns earlier and determine whether additional investigation or risk management actions are needed. This proactive approach becomes increasingly important after commercialization, when products are exposed to larger and more diverse patient populations.
PSUR and PBRER Preparation: Measuring Regulatory Reporting Expertise
Periodic safety reports provide regulatory authorities with ongoing evaluations of a product’s benefit-risk profile. Preparing documents such as Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) requires both safety expertise and strong data integration capabilities.
Sponsors evaluating a PV partner should consider whether the provider can support the complete reporting process, including data collection, case review, signal evaluation, and report preparation. The quality of these reports depends on how effectively safety information from multiple sources is analyzed and presented.
A well-prepared PSUR or PBRER demonstrates that safety monitoring activities are systematic and supported by documented evidence. It also helps regulatory authorities understand whether new information has changed the overall benefit-risk assessment of a product.
Regulatory Reporting: Ensuring Compliance Across Markets
Regulatory reporting requires careful management because requirements vary between regions. Different authorities may have specific expectations regarding report formats, submission timelines, and safety information standards.
A capable pharmacovigilance provider should understand global reporting requirements and maintain processes that support timely submissions. This includes managing reporting schedules, preparing required documentation, and maintaining communication between sponsors and regulatory teams.Effective coordination is especially important for multinational products, where different reporting obligations must be managed simultaneously across regions.
Strong regulatory reporting capabilities reduce compliance risks during both clinical development and post-market stages. They also help ensure that important safety information reaches the appropriate authorities without unnecessary delays.
End-to-End PV Support Extends Safety Management Beyond Trials
The value of pharmacovigilance comes from connecting safety activities across the entire product lifecycle. Clinical trial monitoring provides initial safety information, but post-market surveillance continues to identify new risks as exposure increases.
A complete PV service scope allows sponsors to maintain continuity between development and commercialization. Instead of managing separate safety processes at different stages, organizations can rely on an integrated system that supports consistent data handling, evaluation, and reporting.
For sponsors, evaluating a provider’s full service scope is essential. A partner that can support adverse event processing, signal detection, periodic reporting, and regulatory communication provides a stronger foundation for long-term safety management.
Selecting a Pharmacovigilance Partner with Comprehensive Capability
Choosing a PV partner requires more than checking whether basic reporting functions are available. Sponsors should assess whether the provider has the expertise, systems, and regulatory knowledge needed to manage safety information throughout the product lifecycle.
Tigermed provides integrated clinical development capabilities, including pharmacovigilance solutions that support safety monitoring from clinical trials through post-market activities. With structured safety processes and regulatory expertise, Tigermed helps organizations manage complex safety requirements across different development stages.
A complete approach to pharmacovigilance enables companies to maintain reliable safety oversight after clinical trials end. By selecting a provider with comprehensive pharmacovigilance services, sponsors can better manage emerging risks, meet regulatory expectations, and support ongoing product safety evaluation.
